<I>CS-600, a new anti-inflammatory agent</I>:<I>II. Pharmacological efficacy and ulcerogenic effect of CS-600 and its active metabolite</I>
スポンサーリンク
概要
- 論文の詳細を見る
Anti-inflammatory, analgesic and ulcerogenic activities of CS-600 and its active metabolite were investigated in rats. Anti-carrageenin edema activity of CS-600 (ID<SUB>50</SUB>: 1.2 mg/kg) was as potent as that of the active metabolite (ID<SUB>50</SUB>: 1.3 mg/kg) . Analgesic effect of CS-600 (ID<SUB>50</SUB>: 0.76 mg/kg) on scald pain was also equipotent to that of the metabolite (ID<SUB>50</SUB>: 1.1 mg/kg) . However, gastrointestinal irritancy of CS-600 (UD<SUB>50</SUB>: 16.1 mg/kg for the stomach and 11.5 mg/kg for the intestine) was lower than that of the active metabolite (UD<SUB>50</SUB>: 3.2 mg/kg for the stomach and 3.1 mg/kg for the intestine) . When [<SUP>14</SUP>C] CS-600 was injected into a ligated jejunum in rats, most radioactivity was found as the unchanged CS-600 in the portal blood. These findings indicate that CS-600 is absorbed from the intestine in the less irritating form and that it is converted rapidly to the active metabolite which shows the potent pharmacological efficacy.
- 日本炎症・再生医学会の論文
日本炎症・再生医学会 | 論文
- 新規キノリノン誘導体TA-270の炎症性気道疾患に対する効果
- Salazosulphapyridine, Predonizolone の好中球機能に及ぼす影響と Sodium ferrous citrate との併用効果についての検討
- Sodium ferrous citrate の好中球機能に及ぼす影響
- Mesalazine(Pentasa) の好中球機能に及ぼす影響と Sodium ferrous citrate(SFC) との併用効果についての検討
- 非ウイルスベクターによる細胞標的法の開発